American Capital Advisory’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$83.6K Buy
2,933
+91
+3% +$2.42K 0.03% 181
2026
Q2
$68.4K Sell
2,842
-34
-1% -$889 0.02% 186
2026
Q1
$80.8K Buy
2,876
+63
+2% +$1.68K 0.03% 165
2025
Q4
$70K Sell
2,813
-370
-12% -$9.33K 0.03% 171
2025
Q3
$81.1K Sell
3,183
-104
-3% -$2.57K 0.04% 152
2025
Q2
$79.7K Buy
3,287
+602
+22% +$14K 0.04% 141
2025
Q1
$68K Buy
2,685
+105
+4% +$2.75K 0.04% 149
2024
Q4
$68.4K Sell
2,580
-2
-0.1% -$54 0.04% 143
2024
Q3
$74.7K Buy
2,582
+614
+31% +$17.9K 0.04% 141
2024
Q2
$56.7K Buy
1,968
+100
+5% +$2.75K 0.04% 145
2024
Q1
$76.2K Sell
1,868
-100
-5% -$2.78K 0.07% 124
2023
Q4
$56.7K Buy
+1,968
New +$59.5K 0.04% 145

Other funds holding PFE

American Capital Advisory's PFE Position: Q3 2026 in Review

American Capital Advisory increased its Pfizer (PFE) stake by 3.2% in Q3 2026, buying an estimated $2.42K and bringing the position to 2,933 shares worth $83.6K. The position accounts for 0.03% of the portfolio, ranked #181.

American Capital Advisory first reported a position in PFE in Q4 2023 and has held it in 12 quarters since. 2,899 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

  • American Capital Advisory held 2,933 shares of Pfizer worth $83.6K as of Q3 2026.
  • American Capital Advisory bought 91 Pfizer shares in Q3 2026, an estimated $2.42K.
  • Pfizer made up 0.03% of American Capital Advisory's portfolio in Q3 2026, its #181 holding.
  • American Capital Advisory first reported a position in Pfizer in Q4 2023 and has held it in 12 quarters since.
  • 2,899 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on American Capital Advisory's 13F filing for Q3 2026, filed 28 Oct 2026.